Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 2167-2174

  Schmidt, Hartmut H J ^a   Stuhrmann, Manfred ^a   Shamburek, Robert ^d   Schewe, C Knud ^b   Ebhardt, Margit ^a   Zech, Loren A ^d   Büttner, Carsten ^a   Wendt, Matthias ^a   Beisiegel, Ulrike ^c   Brewer Jr , H Bryan ^d   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; RECEPTOR GENE; SKIN FIBROBLAST; SYMPTOMATOLOGY;

EID: 14444283887     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.6.4840     Document Type: Article

References (44)

1. Goldstein JL, Hobbs HH, Brown MB. 1995 Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw Hill; 1981-2030.
2. Schmidt HH-J, Dugi K, Hill S, Makariou EV, Feuerstein IM, Hoeg JM. 1996 Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol. 77:575-580.
3. Schuster H, Keller C, Wolfram G, Zöllner N. 1995 Ten LDL receptor mutants explain one third of familial hypercholesterolemia in a German sample. Arterioscler Thromb Vas. 15:2176-2180.
4. Innerarity TL, Mahley RW, Weisgraber KH, et al. 1990 Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 31:1337-1349.
5. Pullinger CR, Hennessy LK, Chatterton JE, et al. 1995 Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL-receptor binding affinity. J Clin Invest. 95:1225-1234.
6. Nora JJ, Lortscher RM, Sprangler RD, Bilheimer DW. 1985 I. Familial hypercholesterolemia with "normal" cholesterol in obligate heterozygotes. Am J Med Genet. 22:585-591.
7. Bilheimer DW, East C, Grundy SM, Nora JJ. 1985 II. Clinical studies in a kindred with a kinetic LDL receptor mutation causing familial hypercholesterolemia. Am J Med Genet. 22:593-598.
8. Zuliani G, Vigna GB, Corsini A, Maioli M, Romagnoni F, Fellin R. 1995 Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur J Clin Invest. 25:322-331.
9. Frostegard J, Hamsten A, Gidlund M, Nilsson J. 1990 Low density lipoprotein induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. J Lipid Res. 31:37-44.
10. Schewe CK, Schuster H, Hailer S, Wolfram G, Keller C, Zöllner N. 1994 Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100. Eur J Clin Invest. 24:36-41.
11. Bilheimer JT, Chamoun D, Esfahani M. 1987 Defective 3-ketosteroid reductase activity in a human monocyte-like cell line. J Lipid Res. 28:704-709.
12. Esfahani M, Scerbo L, Devlin TM. 1984 A requirement for cholesterol and its structural features for a human macrophage-like cell line. J Cell Biochem. 25:87-97.
13. Hansen PS, Rüdiger N, Tybjaerg-Hansen A. 1991 Detection of the apoB 3500 mutation (glutamine for arginine) by gene amplification and cleavage with Msp I. J Lipid Res. 32:1229-1233.
14. Hobbs HH, Brown MS, Goldstein JL. 1992 Molecular genetics of the LDL receptor gene and familial hypercholesterolemia. Hum Mutat. 1:445-466.
15. Leitersdorf E, Chakravarti A, Hobbs HH. 1989 Polymorphic DNA haplotypes at the LDL receptor locus. Am J Hum Genet. 44:409-421.
16. Hammond HA, Jin L, Zhong Y, Caskey CT, Chakraborty R. 1994 Evaluation of 13 short tandem repeat loci for use in personal identification applications. Am J Hum Genet. 55:175-189.
17. Goldstein JL, Brown MS. 1974 Binding and degradation of low density lipoproteins by cultured human fibroblasts. J Biol Chem. 249:5153-5162.
18. Goldstein JL, Brown MS. 1979 The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet. 13:259-289.
19. Havel RJ, Eder HA, Bragdon JH. 1955 The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1345-1353.
20. MacFarlane AS. 1958 Efficient trace-labeling of proteins with iodine. Nature. 182:53.
21. Bilheimer DW, Eisenberg S, Levy RI. 1972 The metabolism of VLDL. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 260:212-221.
22. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol (proposed selected method). Clin Chem. 28:1379-1388.
23. Manual of Laboratory Operations. Lipid Research Clinics Program. 1974 Lipid and lipoprotein analysis. Washington DC: Government Printing Office, U.S. Department of Health, Education, and Welfare Publication, National Institutes of Health; 75-628.
24. Havel RJ, Eder HA, Bragdon JH. 1955 The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1345-1353.
25. Bartlett GR. 1959 Phosphorus assay in column chromatography. J Biol Chem. 234:466-468.
26. Berman M, Weiss M. 1978 SAAM manual. Washington, DC: Government Printing Office, U.S. Department of Health, Education, and Welfare Publication, National Institutes of Health; No. 78:180.
27. Morganroth J, Levy RI, McMahom AE, Gotto AM. 1974 Pseudohomozygous type II hyperlipoproteinemia. J Pediatr. 85:639-643.
28. Fujita M, Okamoto S, Shirai K, Saito Y, Yoshida S. 1991 Pseudohomozygous type II hyperlipoproteinemia. Dermatologica. 182:94-97.
29. Rimon D, Cohen L. 1989 Hypercholsterolemic (type II hyperlipoproteinemic) arthritis. J Rheumatol. 16:703-705.
30. Myant MB, Gallagher JJ, Knight BL, et al. 1991 Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb. 11:691-703.
31. Van den Broek AJ, Hollaar L, Schaefer HI, et al. 1994 Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay. Clin Chem. 40:395-399.
32. Lestavel S, Benhamamouch S, Agnani G, et al. 1994 Evidence on non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile. Metabolism. 43:397-402.
33. Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. 1995 Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:290-295.
34. Brown MS, Herz J, Kowal RC, Goldstein JL. 1991 The low-density lipoprotein receptor-related protein: double agent or decoy? Curr Opin Lipidol. 2:65-70.
35. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. 1992 The rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA. 89:9252-9256.
36. Niemeier A, Gafvels M, Heeren J, Meyer N, Angelin B, Beisiegel U. 1996 VLDL, receptor mediates the uptake of human chylomicron remnants in vitro. J Lipid Res. 37:1733-1742.
37. Bohnet K, Pillot T, Visvikis S, Sabolovic N, Siest G. 1996 Apolipoprotein E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res. 37:1316-1324.
38. Takahashi S, Suzuki J, Kohno M, et al. 1995 Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem. 270:15747-15754.
39. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. 1988 Surface location and high affinity for calcium of a 500 kDa liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7:4119-4127.
40. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. 1989 Low density lipoprotein receptor related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA. 86:5810-5814.
41. Brunzell JD, Miller NE, Alaupovic P, et al. 1983 Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. J Lipid Res. 24:12-19.
42. Battey FD, Gafvels ME, FitzGerald DJ, et al. 1994 The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor. J Biol Chem. 269:23268-23273.
43. Kounnas MZ, Argraves WS, Strickland DK. 1992 The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330. J Biol Chem. 267:21162-21166.
44. Obermoeller LM, Warshawsky I, Wardell MR, Bu G. 1997 Differential functions of triplicated repeats suggest two independent roles for the receptor-associated protein as a molecular chaperone. J Biol Chem. 272:10761-10768.